10-Q: electroCore Reports Q2 Revenue Growth Amid Rising Losses

electroCore, Inc. reported a 20% increase in net sales for Q2 2025, reaching $7.38 million, but net losses widened to $3.67 million, alongside a significant decline in cash and marketable securities.

Summary

• Net sales for the three months ended June 30, 2025, increased by 20% to $7.38 million, up from $6.14 million in the prior year period.
• Net sales for the six months ended June 30, 2025, increased by 22% to $14.10 million, compared to $11.58 million in the same period last year.
• Gross profit for the three months ended June 30, 2025, rose to $6.44 million from $5.30 million, with gross margin improving to 87% from 86%.
• Gross profit for the six months ended June 30, 2025, increased to $12.15 million from $9.86 million, with gross margin at 86% compared to 85%.
• Net loss for the three months ended June 30, 2025, widened to $3.67 million, up from $2.66 million in the prior year.
• Net loss for the six months ended June 30, 2025, increased to $7.53 million, compared to $6.16 million in the same period last year.
• Selling, general and administrative expenses increased by 30% to $9.44 million for the three months ended June 30, 2025, primarily due to increased sales and marketing costs, bad debt expense, professional fees, and rent.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $7.40 million as of June 30, 2025, a decrease from $12.22 million at December 31, 2024.
• The company completed the acquisition of NeuroMetrix, Inc. (NURO) on May 1, 2025, with NURO becoming a wholly-owned subsidiary.
• A Loan and Security Agreement was entered into with Avenue Venture Opportunities Fund II, L.P. on August 4, 2025, providing for term loans up to $12.0 million, with $7.5 million funded immediately and an additional $4.5 million available by December 31, 2025, subject to performance milestones.
• The company's stockholders' equity was $1.11 million as of June 30, 2025, which is below Nasdaq's $2.5 million Equity Standard for continued listing.

Sentiment

Score: 4

Explanation: While revenue growth is positive and strategic moves like the NURO acquisition and new debt facility provide some runway, the significant increase in net losses, declining cash reserves, and the immediate Nasdaq listing compliance issue indicate a challenging financial position. The new debt adds financial obligations and covenants. The overall sentiment is cautious due to persistent unprofitability and liquidity concerns, despite commercial progress.

Positives

• Net sales increased by 20% for the three months and 22% for the six months ended June 30, 2025, indicating strong revenue growth.
• Gross margin improved slightly to 87% for the three months and 86% for the six months ended June 30, 2025, reflecting favorable product mix and increased sales.
• The acquisition of NeuroMetrix, Inc. (NURO) on May 1, 2025, expands the company's product portfolio with the Quell platform for chronic pain.
• The new Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P. provides up to $12.0 million in term loans, enhancing liquidity and funding for operations.
• The company secured a new Federal Supply Schedule (FSS) contract effective June 15, 2025, through June 14, 2030, ensuring continued access to the significant VA market.
• The UK National Health Service (NHS) extended the listing of gammaCore therapy through March 17, 2026, with an option for a further two-year extension.
• Truvaga product sales significantly increased, with $2.10 million in net sales for the six months ended June 30, 2025, up from $0.96 million in the prior year period.

Negatives

• Net loss increased significantly, reaching $3.67 million for the three months and $7.53 million for the six months ended June 30, 2025, indicating worsening profitability.
• Selling, general and administrative expenses rose substantially by 30% for the three months and 20% for the six months ended June 30, 2025, driven by increased sales and marketing, bad debt, and professional fees.
• The company's cash, cash equivalents, restricted cash, and marketable securities decreased to $7.40 million as of June 30, 2025, from $12.22 million at December 31, 2024.
• Net cash used in operating activities increased to $5.0 million for the six months ended June 30, 2025, from $4.3 million in the prior year period.
• Stockholders' equity declined to $1.11 million as of June 30, 2025, falling below Nasdaq's $2.5 million Equity Standard, posing a delisting risk.
• A bad debt expense of $548,000 was associated with a TAC-STIM receivable in Q2 2025.
• TAC-STIM net sales decreased to $271,000 for the six months ended June 30, 2025, from $356,000 in the prior year period.

Risks

• The company has experienced significant net losses and negative cash flow from operations since inception and expects this to continue, raising concerns about long-term profitability.
• Future capital requirements are difficult to forecast and depend on many uncontrollable factors; inability to achieve planned operating results or maintain sufficient financial resources could materially and adversely affect the business.
• Revenue concentration risk exists, with sales to the U.S. Department of Veterans Affairs and Department of Defense (VA) accounting for 71.8% of net sales for the three months and 71.1% for the six months ended June 30, 2025.
• Exposure to foreign currency exchange risks related to revenue and operating expenses in currencies other than the U.S. dollar (e.g., British Pound Sterling, Japanese Yen).
• Risks associated with selling products through e-commerce marketplaces, including inventory management challenges, broader competition, potential account suspensions, and loss of brand identity/customer relationships.
• The Loan and Security Agreement contains customary affirmative and negative covenants and events of default, which could restrict operating and financial flexibility.
• A default under the Loan and Security Agreement could lead to acceleration of repayment obligations and Avenue taking control of pledged assets, potentially requiring renegotiation on less favorable terms or immediate cessation of operations.
• Failure to meet Nasdaq's continued listing standards (specifically, stockholders' equity below $2.5 million) could result in delisting, negatively impacting stock price, liquidity, and ability to access capital markets.
• The company is involved in a legal proceeding with UAB Pulsetto regarding patent infringement and trademark violations, which is in its early stages and could impact financial results.

Future Outlook

The company expects to continue incurring net losses in the near future as it focuses on increasing market acceptance of its prescription (Rx) products and general wellness and human performance products. Management intends to make targeted investments in sales and marketing in the second half of 2025 to drive commercial activities. The company believes its current cash position, combined with proceeds from the Tranche 1 loan, expected cash flow from operations, and access to capital through the At-The-Market (ATM) facility and Tranche 2 of the Term Loan, will enable it to fund operating expenses and capital expenditure requirements for at least the next 12 months. Research and development expenses are expected to be higher than comparable periods in 2024.

Management Comments

• We intend to continue to make targeted investments in sales and marketing to continue driving commercial activities.
• We have historically funded our operations from the sale of our common stock, and most recently the convertible debt financing with Avenue, and may continue to do so through utilization of the at-the-market facility or other equity or debt transactions if needed.
• Based on its current assessment, the Company believes its cash, cash equivalents, restricted cash, and marketable securities, plus the net proceeds from Tranche 1 of the Term Loan, and expected cash flow from operations and access to capital through the use of the ATM and Tranche 2 of the Term Loan will enable it to fund its operating expenses and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying financial statements are issued.
• There remain significant risks and uncertainties regarding the Company's business, financial condition and results of operations. The Company's future capital requirements are difficult to forecast and will depend on many factors that are out of its control.

Industry Context

The company operates in the bioelectronic technology and neuromodulation space, focusing on non-invasive therapies for conditions like primary headache and fibromyalgia, as well as general wellness products. The acquisition of NeuroMetrix and its Quell platform positions the company to expand its chronic pain offerings. Continued reliance on government contracts (VA) highlights a key market segment, while the push into direct-to-consumer wellness (Truvaga) indicates diversification efforts. The industry is characterized by ongoing innovation in non-invasive treatments and increasing adoption of bioelectronic solutions, but also faces challenges related to market acceptance, regulatory clearances, and competitive pressures from both traditional and emerging therapies.

Comparison to Industry Standards

• The company's gross margin of 86-87% is generally strong for a medical device company, indicating efficient cost of goods sold relative to revenue. This compares favorably to many hardware-focused medical device companies that often have gross margins in the 60-70% range due to manufacturing complexities.
• The significant increase in selling, general, and administrative (SG&A) expenses (30% in Q2 2025) is a common characteristic of commercial-stage medical technology companies investing heavily in market penetration and sales force expansion. However, the magnitude of the increase, coupled with widening net losses, suggests that revenue growth is not yet outpacing operational costs, which is a critical area for improvement compared to more mature, profitable industry players.
• The high concentration of revenue from the VA (over 70%) is a notable characteristic. While this provides a stable revenue stream, it also exposes the company to significant concentration risk, unlike diversified medical device companies that serve a broader range of healthcare systems, private payers, and international markets.
• The acquisition of NeuroMetrix and its Quell platform for fibromyalgia aligns with industry trends of companies expanding their product portfolios through M&A to capture larger market shares and diversify therapeutic indications. This strategy is common among growth-oriented medical technology firms seeking to leverage existing sales channels and R&D capabilities.
• The company's continued net losses and negative cash flow from operations are typical for early to mid-stage medical device companies that are in the commercialization phase, investing heavily in R&D, sales, and marketing before achieving economies of scale and broad market adoption. More established companies like Medtronic or Boston Scientific, for example, typically demonstrate consistent profitability and positive cash flows from operations.

Management Changes

Corporate Governance

Legal Proceedings

• UAB Pulsetto filed a declaratory judgment action against the company on June 11, 2025, asserting that its non-invasive vagus nerve stimulation product does not infringe the company's U.S. Patent No. 11,446,491.
• The company filed a responsive pleading and counterclaims on July 16, 2025, asserting that Pulsetto's product infringes multiple U.S. patents (Nos. 8,948,873, 9,339,653, 10,874,857, 8,843,210, 9,242,092, 11,623,078, and 10,441,780), and that Pulsetto's commercial conduct infringed Truvaga and gammaCore trademarks, committed false advertising, and unfair competition.
• The lawsuit is in its early stages, with discovery not yet begun.

Related Party Transactions

• The company incurred $30,000 for the three months and $90,000 for the six months ended June 30, 2025, for unrestricted and directed educational grants to the Vagus Nerve Society, which was co-founded by an executive of the company in 2023.
• Happy Holstein Management, LLC, managed by the mother of newly appointed director James C. Theofilos, participated in the company's June 2024 private placement, purchasing warrants to acquire common stock and pre-funded warrants.

Stakeholder Impact

• **Shareholders:** Face increased dilution risk from potential future equity raises (ATM facility, Shelf Registration) and the conversion right granted to Avenue. The decline in stockholders' equity and Nasdaq listing risk could negatively impact share price and liquidity. The new debt adds leverage and repayment obligations.
• **Employees:** Headcount reductions led to separation costs, indicating potential workforce adjustments. Stock-based compensation remains a significant expense, impacting overall compensation structure.
• **Customers (VA/DoD):** Continued strong sales to the VA/DoD, reinforced by a new FSS contract and the addition of Quell Fibromyalgia to the Lovell platform, suggest stable access to key government healthcare providers.
• **Customers (Commercial/Direct-to-Consumer):** Increased investment in sales and marketing, particularly for Truvaga, aims to expand market acceptance and reach, potentially benefiting commercial customers and direct consumers.
• **Creditors (Avenue):** The new Loan and Security Agreement provides Avenue with a senior secured lien on substantially all company assets, enhancing their position as a creditor but also imposing covenants on the company.
• **Suppliers:** The company is actively implementing contingency plans, including alternative sourcing strategies and supplier diversification, to mitigate supply chain risks, which could impact existing supplier relationships.

Next Steps

• Continue targeted investments in sales and marketing to drive commercial activities in the second half of 2025.
• Monitor and manage compliance with the Loan and Security Agreement covenants and restrictions.
• Address the Nasdaq continued listing standards, particularly the stockholders' equity requirement, to avoid delisting.
• Pursue the Tranche 2 funding of $4.5 million by achieving the specified performance milestones before December 31, 2025.
• Utilize the At-The-Market (ATM) facility or other equity/debt transactions if additional capital is needed.
• Continue to commercialize Quell Fibromyalgia, especially within the VA customer base.
• Monitor the review of the guidance document by NICE in 2025, as changes could impact the UK Med Tech Funding Mandate program.

Key Dates

Recommendation

While electroCore demonstrates strong revenue growth and strategic expansion through the NeuroMetrix acquisition and new government contracts, its widening net losses, declining cash position, and the immediate risk of Nasdaq delisting due to insufficient stockholders' equity present significant concerns. The new debt facility provides crucial liquidity but introduces additional financial covenants and obligations. The company is in a critical phase of commercialization and financial stabilization. A 'hold' recommendation is appropriate as the positive commercial momentum is offset by substantial financial and operational risks, requiring investors to monitor the company's ability to achieve profitability, manage its liquidity, and resolve the Nasdaq listing issue.

Keywords

Bioelectronic Technology, Neuromodulation, gammaCore, Truvaga, Quell, SEC Filing, 10-Q, Financial Results, Medical Devices, Chronic Pain, Migraine, Cluster Headache, Fibromyalgia, Vagus Nerve Stimulation, Healthcare, Nasdaq Listing, Liquidity, Debt Financing, SEC, VA Sales, NHS Sales